Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...

Such an "exercise-in-a-pill" treatment could benefit older people, who may have trouble achieving recommended levels of ...

Annovis Bio, Inc. (NYSE: ANVS) announced its financial results for the third quarter ending September 30, 2024, alongside ...

An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...

Kisunla will join lecanemab as an option for the treatment in Japan of early symptomatic Alzheimer's disease. Lecanemab was ...

By Tarun Sai Lomte Exploring the genetic blueprint of cerebrospinal fluid proteins, this study uncovers new markers and ...

Recent research has revealed that alcohol use disorder and Alzheimer’s disease share significant patterns of gene ...

Wa'el Hashad Wa'el Hashad, CEO, Longeveron Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease ...

The Alzheimer's Association hosted a Women's AWARE luncheon in Tulsa, raising awareness and funds for research.

Frailty is a strong predictor of dementia risk, with risk increasing by 40% with each 4-5 additional age-related health conditions.

Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash positio ...

Shares of Acumen Pharmaceuticals fell after its loss widened and results missed analyst expectations in the third quarter. The stock fell 16% to $2.69 in afternoon trading Tuesday. Shares, which had ...